Sorafenib induced tumor lysis syndrome in an advanced hepatocellular carcinoma patient

被引：0

作者：

Wu-Shiung Huang ^{[1
]}

Chang-Hsu Yang ^{[2
]}

机构：

[1] Division of Gastroentero-Hepatology, E-DA Hospital/I-Shou University

[2] Department of Pathology and Laboratory medicine,E-DA Hospital/I-Shou University

来源：

World Journal of Gastroenterology | 2009年 / 15卷 / 35期

关键词：

Sorafenib; Tumor lysis syndrome; Hepatocellular carcinoma; Hemodialysis; Hyperkalemia;

D O I：

暂无

中图分类号：

R735.7 [肝肿瘤];

学科分类号：

100214 ;

摘要：

A 55-year-old male patient with hepatitis B-related liver cirrhosis was found to have advanced hepatocellular carcinoma.His AFP was initially 9828μg/L and rapidly dropped to 5597μg/L in ten days after oral sorafenib treatment.However,he developed acute renal failure, hyperkalemia,and hyperuricemia 30 d after receiving the sorafenib treatment.Tumor lysis syndrome was suspected and intensive hemodialysis was performed. Despite intensive hemodialysis and other supportive therapy,he developed multiple organ failure(liver, renal,and respiratory failure)and metabolic acidosis. The patient expired 13 d after admission.

引用

页码：4464 / 4466

页数：3

共 3 条

[1]

Tumour lysis syndrome: new therapeutic strategies and classification[J] . Mitchell S.Cairo,MichaelBishop.British Journal of Haematology . 2004 (1)

[2]

Management of tumor lysis syndrome: Prevention and treatment[J] . Barbara Holmes Gobel.Seminars in Oncology Nursing . 2002

[3]

Management of tumor lysis syndrome with standard continuous arteriovenous hemodialysis: case report and a review of the literature[J] . Jeffrey R. Schelling,Fadi Z. Ghandour,Theodore J. Strickland,John R. Sedor.Renal Failure . 1998 (4)

← 1 →